237 related articles for article (PubMed ID: 30909788)
1. Hypercalcemia and acute kidney injury induced by eldecalcitol in patients with osteoporosis: a case series of 32 patients at a single facility.
Aihara S; Yamada S; Oka H; Kamimura T; Nakano T; Tsuruya K; Harada A
Ren Fail; 2019 Nov; 41(1):88-97. PubMed ID: 30909788
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety of eldecalcitol in Japanese patients with osteoporosis: a retrospective, large-scale database study.
Takeuchi Y; Saito H; Makishima M; Yokoyama H; Yamaguchi T; Fujii H; Inoue E; Isemura T; Kondo S
J Bone Miner Metab; 2022 Mar; 40(2):275-291. PubMed ID: 35041084
[TBL] [Abstract][Full Text] [Related]
3. Frequency and determinants of serum calcium monitoring during eldecalcitol therapy in patients with osteoporosis.
Ri K; Fukasawa T; Masuda S; Tanaka S; Takeuchi M; Yoshida S; Kawakami K
J Bone Miner Metab; 2023 Nov; 41(6):890-900. PubMed ID: 37897673
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis.
Sakai A; Ito M; Tomomitsu T; Tsurukami H; Ikeda S; Fukuda F; Mizunuma H; Inoue T; Saito H; Nakamura T;
Osteoporos Int; 2015 Mar; 26(3):1193-202. PubMed ID: 25592133
[TBL] [Abstract][Full Text] [Related]
5. Hypercalcaemia-induced acute kidney injury in an older patient with osteoporosis treated with alfacalcidol for denosumab-induced hypocalcaemia.
Yamada S; Matsuo M; Tokumoto M; Ooboshi H
Nephrology (Carlton); 2017 Jul; 22(7):572-573. PubMed ID: 28621008
[No Abstract] [Full Text] [Related]
6. The safety and effectiveness profile of eldecalcitol in a prospective, post-marketing observational study in Japanese male patients with osteoporosis.
Kondo S; Kakihata H; Nishida Y; Furuno Y; Kobayashi Y; Tabata H; Nomura M
J Bone Miner Metab; 2019 Mar; 37(2):292-300. PubMed ID: 29532248
[TBL] [Abstract][Full Text] [Related]
7. The other side of vitamin D therapy:
a case series of acute kidney injury due to malpractice-related vitamin D intoxication
.
Wani M; Wani I; Banday K; Ashraf M
Clin Nephrol; 2016 Nov; 86 (2016)(11):236-241. PubMed ID: 27719737
[TBL] [Abstract][Full Text] [Related]
8. The safety and effectiveness profile of eldecalcitol in a prospective, post-marketing observational study in Japanese patients with osteoporosis: interim report.
Saito H; Kakihata H; Nishida Y; Yatomi S; Nihojima S; Kobayashi Y; Tabata H; Nomura M
J Bone Miner Metab; 2017 Jul; 35(4):456-463. PubMed ID: 27699492
[TBL] [Abstract][Full Text] [Related]
9. Overview of the clinical efficacy and safety of eldecalcitol for the treatment of osteoporosis.
Cui L; Xia W; Yu C; Dong S; Pei Y
Arch Osteoporos; 2022 May; 17(1):74. PubMed ID: 35513519
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of eldecalcitol, a new active vitamin D3 analog, in the bone metabolism of postmenopausal women receiving maintenance hemodialysis.
Sasaki N; Tsunoda M; Ikee R; Hashimoto N
J Bone Miner Metab; 2015 Mar; 33(2):213-20. PubMed ID: 24763728
[TBL] [Abstract][Full Text] [Related]
11. [Current Topics on Vitamin D. Treatment of osteoporosis with eldecalcitol: Its therapeutic efficacy and adverse effect on renal function].
Takeuchi Y
Clin Calcium; 2015 Mar; 25(3):425-32. PubMed ID: 25716816
[TBL] [Abstract][Full Text] [Related]
12. Stimulation of intestinal calcium absorption by orally administrated vitamin D3 compounds: a prospective open-label randomized trial in osteoporosis.
Uenishi K; Tokiwa M; Kato S; Shiraki M
Osteoporos Int; 2018 Mar; 29(3):723-732. PubMed ID: 29273827
[TBL] [Abstract][Full Text] [Related]
13. Treatment of osteoporosis with eldecalcitol, a new vitamin D analog: a comprehensive review and meta-analysis of randomized clinical trials.
Xu Z; Fan C; Zhao X; Tao H
Drug Des Devel Ther; 2016; 10():509-17. PubMed ID: 26869769
[TBL] [Abstract][Full Text] [Related]
14. Acute kidney injury due to excessive and prolonged intramuscular injection of veterinary supplements containing vitamins A, D and E: A series of 16 cases.
De Francesco Daher E; Mesquita Martiniano LV; Lopes Lima LL; Viana Leite Filho NC; de Oliveira Souza LE; Duarte Fernandes PH; da Silva SL; da Silva Junior GB
Nefrologia; 2017; 37(1):61-67. PubMed ID: 27577045
[TBL] [Abstract][Full Text] [Related]
15. Admission calcium levels and risk of acute kidney injury in hospitalised patients.
Thongprayoon C; Cheungpasitporn W; Mao MA; Sakhuja A; Erickson SB
Int J Clin Pract; 2018 Apr; 72(4):e13057. PubMed ID: 29314467
[TBL] [Abstract][Full Text] [Related]
16. A Rare Presentation of Hypermagnesemia Associated with Acute Kidney Injury due to Hypercalcemia.
Horino T; Ichii O; Terada Y
Intern Med; 2019 Apr; 58(8):1123-1126. PubMed ID: 30568149
[TBL] [Abstract][Full Text] [Related]
17. Eldecalcitol for the treatment of osteoporosis.
Noguchi Y; Kawate H; Nomura M; Takayanagi R
Clin Interv Aging; 2013; 8():1313-21. PubMed ID: 24101867
[TBL] [Abstract][Full Text] [Related]
18. Acute kidney injury due to overcorrection of hypovitaminosis D: A tertiary center experience in the Kashmir Valley of India.
Chowdry AM; Azad H; Najar MS; Mir I
Saudi J Kidney Dis Transpl; 2017; 28(6):1321-1329. PubMed ID: 29265043
[TBL] [Abstract][Full Text] [Related]
19. Denosumab in hypercalcemia of malignancy: a case series.
Dietzek A; Connelly K; Cotugno M; Bartel S; McDonnell AM
J Oncol Pharm Pract; 2015 Apr; 21(2):143-7. PubMed ID: 24415364
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of 12 months of monthly minodronate monotherapy and monthly minodronate combination therapy with vitamin K2 or eldecalcitol in patients with primary osteoporosis.
Ebina K; Noguchi T; Hirao M; Kaneshiro S; Tsukamoto Y; Yoshikawa H
J Bone Miner Metab; 2016 May; 34(3):243-50. PubMed ID: 26303222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
